BioCurie develops AI-driven software to accelerate the development and manufacturing of cell, gene, and RNA therapies. This platform integrates into existing workflows to optimize critical process parameters and ensure critical quality attributes. The result is faster, smarter, and more scalable production processes, making advanced genomic medicines more accessible.
Funding
Funding not disclosed
Founders
Product
Problem
The production of cell and gene therapies involves complex bioprocessing workflows that are challenging to optimize, leading to inefficiencies and variability in manufacturing. This complexity can hinder the timely and cost-effective delivery of these advanced therapies to patients.
Solution
Biocurie provides an AI-powered platform designed to enhance decision-making throughout the cell and gene therapy manufacturing lifecycle. The platform integrates with existing bioprocessing data streams to deliver actionable insights for workflow optimization. By leveraging advanced machine learning algorithms, Biocurie aims to improve process robustness, increase yield, and reduce manufacturing timelines. This enables biopharmaceutical companies to accelerate the development and production of life-saving therapies.
Target Audience
Biopharmaceutical companies and contract development and manufacturing organizations (CDMOs) involved in the production of cell and gene therapies.
Features
- AI-driven predictive analytics for bioprocess optimization
- Machine learning models for real-time process monitoring and control
- Data integration capabilities for diverse bioprocessing equipment and LIMS
- Workflow simulation and scenario analysis tools
- Automated anomaly detection and root cause analysis for manufacturing deviations
- Performance benchmarking and continuous improvement recommendations